Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behcet's disease
Kh. Lee et al., Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behcet's disease, ARCH DERM R, 291(7-8), 1999, pp. 374-381
Behcet's disease is a chronic, multisystem disorder characterized by a recu
rrent inflammatory reaction. Antiendothelial cell antibodies have been dete
cted in the serum from patients with autoimmune diseases with presenting va
sculitis and it is assumed that they can induce damage to the endothelial c
ells, In this study, me detected antiendothelial cell antibodies in the ser
um from patients with Behcet"s disease using an enzyme-linked immunosorbent
assay, electrophoresis and immunoblotting. The cytolysis of human dermal m
icrovascular endothelial cells (HDMEC) was measured using a cytotoxicity as
say, The serum from 37.4% of Behcet's disease patients showed IgM antibodie
s against unstimulated HDMEC while the serum from 18.4% of patients showed
an increase in IgM antibody titer after IFN-gamma pretreatment, The frequen
cy of vasculitis was higher in the IgM-positive Behcet"s disease patients t
han in the IgM-negative patients, In Western blotting, IgM-positive Behcet'
s disease serum reacted With the 44 kDa HDMEC surface antigen, whereas IgM-
positive systemic lupus erythematosus serum reacted with the 81 kDa HDMEC s
urface antigen. The reactivity to the 44 kDa protein band was also observed
in cultured human umbilical vein endothelial cells but not in fibroblasts,
A431 cells or SK-MEL-2 cells. Serum from Behcet's disease patients incubat
ed with human complement or mononuclear cells produced no significant lysis
of HDMEC, and cultured HDMEC were resistant to antibody-dependent cell-med
iated cytotoxicity, The results suggest that antibodies against antigens on
the surface of endothelial cells may play a role in inducing vasculitis in
Behcet's disease, not through a direct toxic effect of an antiendothelial
cell antibody but by an indirect effect involving the activation of endothe
lial cells to produce cytokines.